Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | S100A9 | P06702 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 3/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30851311 | 1.00 | SSTR4 (0.42) | SSTR4AURKAKDRAURKBULK1 | |
| SCHEMBL22437230 | 0.87 | SSTR4 (0.36) | SSTR4AURKAKDRAURKBULK1 | |
| SCHEMBL29749337 | 0.83 | SSTR4 (0.44) | SSTR4AURKAKDRAURKBULK1 | |
| SCHEMBL22638138 | 0.83 | SSTR4 (0.44) | SSTR4AURKAKDRAURKBULK1 | |
| SCHEMBL2391289 | 0.82 | SSTR4 (0.46) | SSTR4CYP11B1CYP11B2NOTUMCFTR | |
| SCHEMBL21513137 | 0.81 | AAK1 (0.35) | SSTR4AURKAKDRAURKBCYP11B1 | |
| SCHEMBL2414662 | 0.81 | SSTR4 (0.40) | SSTR4AURKAKDRAURKBULK1 | |
| SCHEMBL2713610 | 0.80 | SSTR4 (0.49) | SSTR4CYP11B1CYP11B2S1PR4 | |
| SCHEMBL13281923 | 0.80 | SSTR4 (0.52) | SSTR4AURKAKDRAURKBCYP11B1 | |
| SCHEMBL5942469 | 0.79 | AURKA (0.42) | SSTR4AURKAKDRAURKBULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656636-A1 | CRYSTAL FORM AND USE OF PARP 7 INHIBITOR AND SALT THEREOF | QILU PHARMACEUTICAL CO., LTD. (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-4644385-A1 | TIPARP INHIBITOR COMPOUNDS | AbbVie Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250333394-A1 | Tiparp Inhibitor Compounds | ABBVIE INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| WO-2024156286-A1 | CRYSTAL FORM AND USE OF PARP 7 INHIBITOR AND SALT THEREOF | 齐鲁制药有限公司 | 2024-08-02 | — | — | WO | disclosed |
| WO-2024149378-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | 上海超阳药业有限公司 | 2024-07-18 | — | — | WO | disclosed |
| EP-4378938-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-118084936-A | Three-ring-containing compound and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117777099-A | PARP7 inhibitors and uses thereof | 诺沃斯达药业(上海)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| EP-2590974-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013057711-A1 | QUINAZOLINE DERIVATIVES AS PI3K MODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013001445-A1 | SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2013-01-03 | — | — | WO | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | SSTR4 3869/4885AURKA 2107/4885KDR 1064/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | SSTR4 3869/4885AURKA 2107/4885KDR 1064/4885 |
| US-20250333394-A1 | Tiparp Inhibitor Compounds | TIPARP, TIPRL, TPP1 | SSTR4 4679/4885AURKA 1751/4885KDR 3895/4885 |
| US-20240351997-A1 | NOVEL PARP7 INHIBITOR AND USE THEREOF | PARP6, PARP4, PARP3 | SSTR4 4853/4885AURKA 496/4885KDR 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.